Overview

Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the safety and efficacy of HS-10234 versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with chronic hepatitis B virus (HBV) infection.
Phase:
Phase 3
Details
Lead Sponsor:
Jiangsu Hansoh Pharmaceutical Co., Ltd.